People · Operator
Named in public records as an officer, director or promoter · active 2021–2021 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Scopus BioPharma Inc. | — | Pharmaceuticals | Series A | $19.1M | $161.3M | 2021 |
David P. Weild at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David P. Weild on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joshua Lamstein | 1 | 5 |
| Ira Scott Greenspan | 1 | 3 |
| David A. Buckel | 1 | 2 |
| Joshua R. Lamstein | 1 | 2 |
| Robert J. Gibson | 1 | 2 |
| Paul J. Hopper | 1 | 1 |
| Paul R. Hopper | 1 | 1 |
| Morris C. Laster | 1 | 1 |
| Paul E. Hopper | 1 | 1 |
| Raphael A. Hofstein | 1 | 1 |
| Ashish P. Sanghrajka | 1 | 1 |
| David S. Battleman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.